Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 9
2004 1
2005 7
2006 11
2007 6
2008 7
2009 10
2010 8
2011 5
2012 7
2013 5
2014 13
2015 16
2016 17
2017 24
2018 18
2019 16
2020 20
2021 18
2022 20
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year

Filters applied: . Clear all
Page 1
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S. Adnan Awad S, et al. Among authors: aittokallio t. Cell Rep Med. 2024 Apr 10:101521. doi: 10.1016/j.xcrm.2024.101521. Online ahead of print. Cell Rep Med. 2024. PMID: 38653245 Free article.
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer HA, Look AT, Herling M, Moriggl R. Suske T, et al. Among authors: aittokallio t. J Clin Invest. 2024 Apr 15;134(8):e168536. doi: 10.1172/JCI168536. J Clin Invest. 2024. PMID: 38618957 Free PMC article.
Tutorial on survival modeling with applications to omics data.
Zhao Z, Zobolas J, Zucknick M, Aittokallio T. Zhao Z, et al. Among authors: aittokallio t. Bioinformatics. 2024 Mar 4;40(3):btae132. doi: 10.1093/bioinformatics/btae132. Bioinformatics. 2024. PMID: 38445722 Free PMC article.
Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T. Chen Y, et al. Among authors: aittokallio t. Nat Protoc. 2024 Jan;19(1):60-82. doi: 10.1038/s41596-023-00903-x. Epub 2023 Nov 23. Nat Protoc. 2024. PMID: 37996540 Review.
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkönen M, von Schantz-Fant С, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J. Denisova OV, et al. Among authors: aittokallio t. Mol Oncol. 2023 Sep;17(9):1803-1820. doi: 10.1002/1878-0261.13488. Epub 2023 Jul 26. Mol Oncol. 2023. PMID: 37458534 Free PMC article.
226 results